MedTrace Logo

Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization

NCT01350323 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2011-05-09

No results posted yet for this study

Summary

This is a pilot, prospective, interventional, case-control study investigating aqueous levels of vascular endothelial growth factor (VEGF) in eyes with AMD-related neovascularization treated with intravitreal bevacizumab at the Medical Retina Department, University of Molise, Campobasso.

Conditions

  • Age-related Macular Degeneration

Interventions

PROCEDURE

Aqueous sample

Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)

PROCEDURE

Aqueous sample

Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)

PROCEDURE

Aqueous sample

Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)

PROCEDURE

Aqueous sample

Aqueous sample (0.1ml)

Sponsors & Collaborators

  • University of Molise

    lead OTHER

Principal Investigators

  • Roberto dell'Omo, MD · University of Molise

  • Ciro Costagliola, Professor · University of Molise

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01350323 on ClinicalTrials.gov